{"id":"https://openalex.org/W2946643333","doi":null,"title":"Pembrolizumab Improved Survival vs Ipilimumab in Advanced Melanoma","display_name":"Pembrolizumab Improved Survival vs Ipilimumab in Advanced Melanoma","publication_year":2015,"publication_date":"2015-04-19","ids":{"openalex":"https://openalex.org/W2946643333","mag":"2946643333"},"language":"en","primary_location":{"id":"mag:2946643333","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/melanoma/pembrolizumab-improved-survival-vs-ipilimumab-advanced-melanoma","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111948575","display_name":"Leah Lawrence","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Leah Lawrence","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5111948575"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9309999942779541},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.6639999747276306},{"id":"https://openalex.org/keywords/ctla-4-inhibitors","display_name":"CTLA-4 inhibitors","score":0.9639999866485596},{"id":"https://openalex.org/keywords/comparative-treatment-efficacy","display_name":"comparative treatment efficacy","score":0.421999990940094}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9107978343963623},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8911374807357788},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7030931711196899},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.550176203250885},{"id":"https://openalex.org/C2775832928","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Expanded access","level":2,"score":0.4250606894493103},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42097288370132446},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40892964601516724},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2560858726501465},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.21822082996368408},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.12958520650863647}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2946643333","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/melanoma/pembrolizumab-improved-survival-vs-ipilimumab-advanced-melanoma","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2001502818","https://openalex.org/W2152897456","https://openalex.org/W2985767309","https://openalex.org/W2941550550","https://openalex.org/W2941772400","https://openalex.org/W2941437555","https://openalex.org/W2733770133","https://openalex.org/W4231345949","https://openalex.org/W2804569878","https://openalex.org/W2940475540"],"abstract_inverted_index":{"Treatment":[0],"with":[1,17],"pembrolizumab":[2],"resulted":[3],"in":[4,19],"an":[5],"estimated":[6],"6-month":[7],"PFS":[8],"rate":[9],"that":[10,14],"was":[11],"almost":[12],"double":[13],"of":[15],"treatment":[16],"ipilimumab":[18],"advanced":[20],"melanoma":[21],"patients.":[22]},"counts_by_year":[],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2019-05-29T00:00:00"}